Table 2.
Crude and adjusted predictors of missing a medical or ARV visit in the first six months on ART in Johannesburg, South Africa (n = 4476)
| Medical visits | ARV visits | ||||
|---|---|---|---|---|---|
| Variable |
Crude RR (95% CI) |
Adjusted RR† (95% CI) |
Crude RR (95% CI) |
Adjusted RR† (95% CI) |
|
| Sex | Female | Reference | Reference | Reference | Reference |
| Male | 1.15 (1.05-1.27) | 1.16 (1.05-1.28) | 1.14 (1.03-1.28) | 1.15 (1.02-1.28) | |
| Baseline BMI | ≥17.5 | Reference | Reference | Reference | Reference |
| < 17.5 | 1.11 (1.00-1.24) | 1.09 (0.97-1.22) | 1.24 (1.09-1.40) | 1.22 (1.08-1.39) | |
| Age at ART initiation | ≥ 50 | Reference | Reference | Reference | Reference |
| 40-49.9 | 1.11 (0.92-1.35) | 1.15 (0.94-1.40) | 1.00 (0.80-1.25) | 1.00 (0.80-1.26) | |
| 30-39.9 | 1.04 (0.87-1.25) | 1.07 (0.89-1.30) | 1.08 (0.88-1.33) | 1.08 (0.87-1.33) | |
| 25-29.9 | 1.07 (0.87-1.32) | 1.10 (0.89-1.37) | 1.01 (0.80-1.29) | 1.03 (0.81-1.32) | |
| 18-24.9 | 1.10 (0.83-1.45) | 1.13 (0.86-1.51) | 1.22 (0.91-1.65) | 1.23 (0.90-1.67) | |
| Baseline CD4 count (cells/mm3) |
100-200 | Reference | Reference | Reference | Reference |
| 51-100 | 0.89 (0.78-1.01) | 0.88 (0.77-1.00) | 0.93 (0.81-1.08) | 0.95 (0.83-1.07) | |
| 0-50 vs. | 1.00 (0.90-1.12) | 0.98 (0.88-1.09) | 0.99 (0.88-1.12) | 0.93 (0.80-1.07) | |
| Baseline Hb (ug/dL) | ≥ 10.0 | Reference | Reference | Reference | Reference |
| < 10.0 | 1.01 (0.91-1.13) | 1.02 (0.92-1.14) | 1.00 (0.89-1.14) | 1.00 (0.88-1.13) | |
| Baseline WHO stage | I/II | Reference | Reference | Reference | Reference |
| III/IV | 1.04 (0.94-1.14) | 1.03 (0.93-1.14) | 1.06 (0.95-1.19) | 1.03 (0.92-1.16) | |
| Baseline NRTI | d4T | Reference | Reference | Reference | Reference |
| AZT | 1.13 (0.86-1.48) | 1.10 (0.84-1.44) | 0.99 (0.71-1.39) | 0.98 (0.70-1.38) | |
| Baseline NNRTI | EFV | Reference | Reference | Reference | Reference |
| NVP | 1.13 (0.96-1.33) | 1.18 (1.00-1.40) | 1.04 (0.85-1.26) | 1.05 (0.86-1.29) | |
†Relative risks (RR) are from a log-binomial regression model also adjusted for baseline BMI, age, baseline CD4, baseline haemoglobin, baseline WHO stage and baseline regimen
CI, confidence interval; ART, antiretroviral therapy; BMI, body mass index; Hb, haemoglobin; d4T, stavudine; AZT, zidovudine; EFV, efavirenz; NVP, nevirapine; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor